Bilastine
- Generic Name
- Bilastine
- Brand Names
- Blexten
- Drug Type
- Small Molecule
- Chemical Formula
- C28H37N3O3
- CAS Number
- 202189-78-4
- Unique Ingredient Identifier
- PA1123N395
- Background
Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
- Indication
For symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older .
- Associated Conditions
- Chronic Spontaneous Urticaria, Seasonal Allergic Rhinitis
Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
- Conditions
- Urticaria
- Interventions
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Grupo de Alergología Clínica y Experimental
- Target Recruit Count
- 150
- Registration Number
- NCT01940393
- Locations
- 🇨🇴
Medellin, Medellin, Antioquia, Colombia
Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 239
- Registration Number
- NCT01400828
- Locations
- 🇰🇷
Yonsei University college of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of
Bilastine Updosing - Characterization of Underlying Mechanisms
- First Posted Date
- 2011-01-06
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 20
- Registration Number
- NCT01271075
- Locations
- 🇩🇪
Charité-Universitätsmedizin Berlin, Berlin, Germany
Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 650
- Registration Number
- NCT01127620
Oral Bioavailability of Bilastine
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 12
- Registration Number
- NCT01124123
- Locations
- 🇪🇸
Unidad de Investigacion Clinica. Clinica Universidad de Navarra, Pamplona, Navarra, Spain
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 720
- Registration Number
- NCT01108783
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 36
- Registration Number
- NCT01081574
- Locations
- 🇩🇪
Universitäts-Hautklinik, Kiel, Germany
🇦🇺Princess Margaret Hospital for Children, Subiaco, Western Australia, Australia
🇦🇺Royal Children's Hospital, Parkville, Victoria, Australia
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
- Conditions
- Hay FeverAllergic ConjunctivitisHypersensitivitySeasonal Allergic Rhinitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 805
- Registration Number
- NCT00574379
- Locations
- 🇺🇸
Lovelace Scientific Resources, Austin, Texas, United States
🇺🇸Live Oak Allergy and Asthma, San Antonio, Texas, United States
🇺🇸MetaClin Research Inc., Austin, Texas, United States
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
- Conditions
- Hay FeverRhinoconjunctivitisSeasonal Allergic Rhinitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 502
- Registration Number
- NCT00574210
- Locations
- 🇨🇦
Allied Research International - Cetero Research, Mississauga, Ontario, Canada
Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 683
- Registration Number
- NCT00504933
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.